“…In such scenarios a surrogate gene, also called as reporter gene (e.g., herpes simplex virus type 1-thymidine kinase [HSV1-tk], norepinephrine transporter [NET], sodium iodide symporter [NIS]), that can be targeted using a radiochemical probe can be expressed as a fusion protein or as a separate protein using bi-or multi-cistronic vectors that will ensure a stoichiometric expression of the gene product. [10][11][12][13][14] For gene therapy involving RNAi technology, direct labeling of RNAi with a suitable radiolabeled conjugate can provide information about the delivery of the vector. 15 Irrespective of the type of imaging approach, the design, function, and pharmacokinetic behavior of the radiochemical probe is the most crucial determinant in ensuring that the signal obtained using the radiochemical probe directly correlates to the efficacy of gene therapy.…”